Core Insights - Teva Pharmaceuticals and Sanofi announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, showing durable clinical and endoscopic efficacy over 44 weeks in patients with ulcerative colitis and Crohn's disease [2][6] - The study reinforces the efficacy observed in the previous phase 2b induction study, indicating that duvakitug has the potential to be a best-in-class therapy for inflammatory bowel disease [3][4] Study Details - The RELIEVE UCCD LTE study is a double-blind randomized study evaluating the long-term efficacy, safety, and tolerability of duvakitug in patients who initially responded to the induction phase [2][15] - A total of 130 patients who responded to duvakitug in the induction study entered a 44-week maintenance period, receiving either 450 mg or 900 mg doses every four weeks [4][15] Efficacy Results - At week 44, 58% of patients on the 900 mg dose and 47% on the 450 mg dose achieved clinical remission in ulcerative colitis, while 55% on the 900 mg dose and 41% on the 450 mg dose achieved endoscopic response in Crohn's disease [10] - Consistent benefits were observed across additional efficacy endpoints for both conditions [10] Safety Profile - Both doses of duvakitug were well tolerated, with the most frequent adverse events being upper respiratory tract infection, nasopharyngitis, Crohn's disease, and hypertension, consistent with the phase 2b induction study [5][9] Future Developments - Phase 3 studies for duvakitug are currently underway, with the collaboration between Teva and Sanofi focusing on co-developing and co-commercializing the therapy for ulcerative colitis and Crohn's disease [6][18] - The companies aim to announce additional indications for duvakitug later this year, emphasizing their commitment to providing innovative treatment options [4][6]

Core Viewpoint - Teva Pharmaceuticals and Sanofi announced positive results from the RELIEVE UCCD long-term extension study of duvakitug, showing durable clinical and endoscopic efficacy in patients with ulcerative colitis and Crohn's disease over a 44-week period [2][4][5]. Group 1: Study Results - The RELIEVE UCCD LTE study demonstrated that duvakitug maintained durable efficacy for an additional 44 weeks in patients who initially responded to the induction phase [8]. - In the study, 58% of patients treated with 900 mg and 47% with 450 mg of duvakitug achieved clinical remission in ulcerative colitis, while 55% with 900 mg and 41% with 450 mg achieved endoscopic response in Crohn's disease [9]. - The study enrolled 130 patients who received either 450 mg or 900 mg of duvakitug every four weeks for up to 58 weeks, with both doses being well tolerated [4][8]. Group 2: Safety and Tolerability - The most frequently observed adverse events (≥5% of all patients) included upper respiratory tract infection, nasopharyngitis, Crohn's disease, and hypertension, consistent with the phase 2b induction study [4][8]. - Safety data from the long-term extension study were consistent with the findings from the induction study, reinforcing the tolerability of duvakitug [8]. Group 3: Future Development - Teva and Sanofi are committed to advancing duvakitug, with ongoing phase 3 studies aimed at providing new treatment options for patients with inflammatory bowel disease [5][17]. - The collaboration between Teva and Sanofi involves co-developing and co-commercializing duvakitug, sharing development costs and profits in major markets [17].

Core Insights - Abivax announced the acceptance of 22 abstracts related to obefazimod for inflammatory bowel disease (IBD) at the ECCO 2026 Congress, including an oral presentation on preclinical anti-fibrotic findings [2][6] Group 1: Clinical Data and Findings - The accepted abstracts from the Phase 3 ABTECT Induction Trials demonstrate obefazimod's clinical activity across various patient subpopulations, showing downregulation of pro-inflammatory cytokines (IL-17A, IL-6) and early symptomatic improvement [3][8] - The data reinforces obefazimod's favorable tolerability profile, indicating its potential as a treatment option for IBD [3][6] Group 2: Anti-Fibrotic Activity - An oral presentation will address obefazimod's anti-fibrotic activity, which is significant for addressing fibrosis, a serious complication in IBD, particularly in Crohn's disease [4][5] - The preclinical study assessed obefazimod's anti-fibrotic effects in both in vitro and in vivo models, providing initial evidence of its activity [5][8] Group 3: Presentation Details - The oral presentation titled "Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease" is scheduled for February 21, 2026, at the ECCO Congress [7][8] - The breadth of scientific evidence includes 1 oral presentation, 5 digital oral presentations, and 16 posters, reflecting an expanding dataset for obefazimod [8]